STE — STERIS plc

STERIS plc Q2 Fiscal 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Grew 10% year-over-year; constant currency organic revenue increased by 9%.
• Gross Margin: Improved by 60 basis points to 44.3%.
• EBIT Margin: Increased by 90 basis points to 23.1%.
• Net Income: $244.5 million from continuing operations.
• Adjusted Earnings per Diluted Share: $2.47, a 15% increase compared to the prior year.
• Free Cash Flow: Strong performance with $527.7 million in the first half of fiscal 2026.
• Total Debt: $1.9 billion, with a gross to EBITDA ratio of approximately 1.2x.

2. Strategic Updates and Business Highlights

• Healthcare Segment: Constant currency organic revenue grew 9%, with service revenue up 13% and consumables up 10%. Capital equipment revenue increased by 4%, supported by a backlog exceeding $400 million.
• AST Segment: Constant currency organic revenue increased by 7%, with service growth of 13%. EBIT margins rose to 45.3%.
• Life Sciences Segment: Achieved 12% constant currency organic revenue growth, driven by a 39% increase in capital equipment shipments.
• Operational Efficiency: Positive pricing and productivity improvements offset inflation and tariff costs.

3. Forward Guidance and Outlook

• Revenue Growth: Revised guidance for fiscal 2026 now anticipates 8% to 9% as-reported revenue growth and 7% to 8% constant currency organic revenue growth.
• Earnings Outlook: Adjusted earnings guidance increased to a range of $10.15 to $10.30 per share.
• EBIT Margin: Expected to improve by 10 to 20 basis points for the year.
• Free Cash Flow: Increased guidance to $850 million for fiscal 2026.
• Capital Expenditures: Remains unchanged at approximately $375 million.

4. Challenges and Points of Concern

• Tariffs and Inflation: The company faced headwinds from tariffs (90 basis points impact) and material/labor inflation (130 basis points impact), which affected margins.
• Service Growth Sustainability: While service revenue has been strong, there are concerns about potential slowdowns as labor costs normalize.
• Capital Equipment Timing: Growth in capital equipment is subject to shipment timing, which may affect future revenue.

5. Notable Q&A Insights

• AST Services Growth: Continued stable volumes from medtech customers and recovery in bioprocessing are driving double-digit service growth, with expectations for continued strength.
• Healthcare Service Dynamics: The service business is performing well due to traditional equipment servicing and IMS repair, but a slowdown in growth rates is anticipated as labor costs stabilize.
• Geographic Performance: Strong growth is noted in the U.S. healthcare market, with recovery in other regions.
• Capacity Expansion: The company is actively expanding capacity in AST, though it is a lengthy process.
• Single-Use Scopes: There is a niche for single-use scopes, particularly in smaller diameters, but large diameter scopes remain dominant in the market.

Overall, STERIS reported a strong quarter with positive revenue growth and improved margins, while also navigating challenges related to inflation and tariffs. The company remains optimistic about its outlook for the remainder of fiscal 2026.